Speakers at CHEST 2026 walked through the first CHEST guideline for non-CF adult bronchiectasis, including which preventive therapy to start first.
News|Articles|May 12, 2025
- June 2025
- Volume 31
- Issue Spec. No. 7
- Pages: SP400-SP401
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
Author(s)Mary Caffrey
Advertisement
Advertisement
The recent readout of SKYSCRAPER-01 (NCT04294810) filled in details about the phase 3 trial for tiragolumab, an anti-TIGIT antibody, which failed to make a meaningful difference when combined with atezolizumab (Tecentriq, Genentech/Roche) for untreated patients with non–small cell lung cancer (NSCLC).1 At first glance, the results confirm pharma’s current verdict: T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a bust as a target for immune checkpoint regulation.
Related to this article
A higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.
On the opening day of CHEST 2026, the organization's flagship journal highlights a trio of key papers with practice-changing results for COPD.
Selected presentations from “Reframing COPD: Phenotypes, Outcomes, Therapeutics, and the Future of Care Delivery,” a session on the opening day of CHEST 2026.
Non-Hodgkin lymphoma mortality trends impact lower-income, less-educated communities, highlighting health disparities and needs for health equity.
Older patients with obstructive sleep apnea (OSA) had more cardiometabolic disease and poorer reported sleep quality than younger patients.
SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.
Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
Advertisement
Advertisement